Robbins Farley’s Definium Therapeutics DFTX Stock Holding History

Robbins Farley’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$530	Hold	28	–	–	﹤0.01%	125
2025 Q4	$375	Hold	28	–	–	﹤0.01%	133
2025 Q3	$331	Hold	28	–	–	﹤0.01%	160
2025 Q2	$182	Hold	28	–	–	﹤0.01%	164
2025 Q1	$164	Hold	28	–	–	﹤0.01%	147
2024 Q4	$195	Hold	28	–	–	﹤0.01%	146
2024 Q3	$160	Hold	28	–	–	﹤0.01%	145
2024 Q2	$202	Hold	28	–	–	﹤0.01%	157
2024 Q1	$264	Hold	28	–	–	﹤0.01%	156
2023 Q4	$103	Hold	28	–	–	﹤0.01%	166
2023 Q3	$88	Buy	+28	New	+$115	﹤0.01%	178
2023 Q2	–	Sell	-28	Closed	-$89	–	186
2023 Q1	$89	Hold	28	–	–	﹤0.01%	191
2022 Q4	$62	Hold	28	–	–	﹤0.01%	181
2022 Q3	$0	Buy	+28	New	+$269	﹤0.01%	154
2022 Q2	–	Sell	-23	Closed	–	–	152
2022 Q1	$0	Buy	23 +8	+53%	+$139	﹤0.01%	162
2021 Q4	$0	Buy	15 +7	+88%	+$223	﹤0.01%	194
2021 Q3	$0	Buy	+8	New	+$346	﹤0.01%	181

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Robbins Farley's DFTX Position: Q1 2026 in Review

Robbins Farley held its Definium Therapeutics (DFTX) position steady in Q1 2026 at 28 shares worth $530. The position accounts for ﹤0.01% of the portfolio, ranked #125.

Robbins Farley first reported a position in DFTX in Q3 2021 and has held it in 17 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

Robbins Farley held 28 shares of Definium Therapeutics worth $530 as of Q1 2026.
Robbins Farley left its Definium Therapeutics share count unchanged in Q1 2026.
Definium Therapeutics made up ﹤0.01% of Robbins Farley's portfolio in Q1 2026, its #125 holding.
Robbins Farley first reported a position in Definium Therapeutics in Q3 2021 and has held it in 17 quarters since.
247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Robbins Farley's 13F filing for Q1 2026, filed 17 Apr 2026.